OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study
Lucas Hendrik Overeem, Kristin Sophie Lange, Mira Pauline Fitzek, et al.
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 23
Lucas Hendrik Overeem, Kristin Sophie Lange, Mira Pauline Fitzek, et al.
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 23
Showing 23 citing articles:
A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response
Ja Bin Hong, Kristin Sophie Lange, Lucas Hendrik Overeem, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 934-934
Open Access | Times Cited: 41
Ja Bin Hong, Kristin Sophie Lange, Lucas Hendrik Overeem, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 934-934
Open Access | Times Cited: 41
Switching anti-CGRP monoclonal antibodies in chronic migraine: real-world observations of erenumab, fremanezumab and galcanezumab
Jamie Talbot, Rebecca Stuckey, Natasha Wood, et al.
European Journal of Hospital Pharmacy (2024), pp. ejhpharm-003779
Closed Access | Times Cited: 11
Jamie Talbot, Rebecca Stuckey, Natasha Wood, et al.
European Journal of Hospital Pharmacy (2024), pp. ejhpharm-003779
Closed Access | Times Cited: 11
Switching CGRP(r) MoAbs in migraine: what evidence?
William Wells-Gatnik, Paolo Martelletti
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 5, pp. 327-333
Closed Access | Times Cited: 9
William Wells-Gatnik, Paolo Martelletti
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 5, pp. 327-333
Closed Access | Times Cited: 9
Therapeutic patterns and migraine disease burden in switchers of CGRP-targeted monoclonal antibodies – insights from the German NeuroTransData registry
Ja Bin Hong, Heike Israel-Willner, Andreas Peikert, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 7
Ja Bin Hong, Heike Israel-Willner, Andreas Peikert, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 7
Switching between anti-calcitonin gene-related peptide monoclonal antibodies: A comparison of monthly and quarterly dosing
Keiko Ihara, Seiya Ohtani, Narumi Watanabe, et al.
Journal of the Neurological Sciences (2023) Vol. 453, pp. 120811-120811
Closed Access | Times Cited: 13
Keiko Ihara, Seiya Ohtani, Narumi Watanabe, et al.
Journal of the Neurological Sciences (2023) Vol. 453, pp. 120811-120811
Closed Access | Times Cited: 13
Real-world effectiveness of erenumab in Japanese patients with migraine
Keisuke Suzuki, Shiho Suzuki, Tomohiko Shiina, et al.
Heliyon (2024) Vol. 10, Iss. 4, pp. e26568-e26568
Open Access | Times Cited: 5
Keisuke Suzuki, Shiho Suzuki, Tomohiko Shiina, et al.
Heliyon (2024) Vol. 10, Iss. 4, pp. e26568-e26568
Open Access | Times Cited: 5
Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: a multicentre retrospective real-world analysis from Germany
Armin Scheffler, P Wenzel, Merle Bendig, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 5
Armin Scheffler, P Wenzel, Merle Bendig, et al.
The Journal of Headache and Pain (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 5
Efficacy and Safety of Switching Between Anti-CGRP Monoclonal Antibodies: A Detailed Monthly and Long-term Follow-up Study and Literature Review
Kota Oshima, Keiko Ihara, Narumi Watanabe, et al.
Internal Medicine (2025)
Open Access
Kota Oshima, Keiko Ihara, Narumi Watanabe, et al.
Internal Medicine (2025)
Open Access
Pharmacological differences and switching among anti‐CGRP monoclonal antibodies: A narrative review
Giorgio Dalla Volta, Antonio Munafò, Andrea Burgalassi, et al.
Headache The Journal of Head and Face Pain (2025)
Closed Access
Giorgio Dalla Volta, Antonio Munafò, Andrea Burgalassi, et al.
Headache The Journal of Head and Face Pain (2025)
Closed Access
Switching between anti-cgrp monoclonal antibodies in migraine prophylaxis
Michail Vikelis, Dimitrios Rikos, Andreas A. Argyriou, et al.
Expert Review of Neurotherapeutics (2025)
Closed Access
Michail Vikelis, Dimitrios Rikos, Andreas A. Argyriou, et al.
Expert Review of Neurotherapeutics (2025)
Closed Access
Real-World Lessons with Fremanezumab as the Third Available CGRP Monoclonal Antibody in a Third-Level Hospital: Focus on the Factors Predicting Response
Marcos Polanco-Fernandez, Gabriel Gárate, Julia Sánchez-Gudín, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1054-1054
Open Access
Marcos Polanco-Fernandez, Gabriel Gárate, Julia Sánchez-Gudín, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1054-1054
Open Access
A real‐world prospective observational study of eptinezumab in Asian patients with migraine
Yi Jing Zhao, Jonathan Ong, Sumit Kumar Sonu, et al.
Headache The Journal of Head and Face Pain (2024) Vol. 64, Iss. 7, pp. 810-824
Open Access | Times Cited: 3
Yi Jing Zhao, Jonathan Ong, Sumit Kumar Sonu, et al.
Headache The Journal of Head and Face Pain (2024) Vol. 64, Iss. 7, pp. 810-824
Open Access | Times Cited: 3
Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis
Jaime Fernández-Bravo-Rodrigo, Iván Cavero‐Redondo, Maribel Lucerón‐Lucas‐Torres, et al.
European Journal of Pharmacology (2024) Vol. 976, pp. 176702-176702
Closed Access | Times Cited: 3
Jaime Fernández-Bravo-Rodrigo, Iván Cavero‐Redondo, Maribel Lucerón‐Lucas‐Torres, et al.
European Journal of Pharmacology (2024) Vol. 976, pp. 176702-176702
Closed Access | Times Cited: 3
Potential Predictors of Response to CGRP Monoclonal Antibodies in Chronic Migraine: Real-World Data
Carmen Sánchez-Rodríguez, Ana Beatriz Gago‐Veiga, David García-Azorín, et al.
Current Pain and Headache Reports (2023)
Closed Access | Times Cited: 7
Carmen Sánchez-Rodríguez, Ana Beatriz Gago‐Veiga, David García-Azorín, et al.
Current Pain and Headache Reports (2023)
Closed Access | Times Cited: 7
Twelve-month efficacy of CGRP monoclonal antibodies and predictive value of short-term response: results of an Australian multicentre study
Jason C. Ray, Linda J. Dalic, Josephine Baker, et al.
BMJ Neurology Open (2024) Vol. 6, Iss. 1, pp. e000547-e000547
Open Access | Times Cited: 2
Jason C. Ray, Linda J. Dalic, Josephine Baker, et al.
BMJ Neurology Open (2024) Vol. 6, Iss. 1, pp. e000547-e000547
Open Access | Times Cited: 2
Preventive Treatment of Migraine
Richard B. Lipton
CONTINUUM Lifelong Learning in Neurology (2024) Vol. 30, Iss. 2, pp. 364-378
Closed Access | Times Cited: 2
Richard B. Lipton
CONTINUUM Lifelong Learning in Neurology (2024) Vol. 30, Iss. 2, pp. 364-378
Closed Access | Times Cited: 2
Anti-CGRP basierte Migränemedikamente – eine Übersicht der Studienlage
Paul Triller, Bianca Raffaelli
Fortschritte der Neurologie · Psychiatrie (2024) Vol. 92, Iss. 07/08, pp. 277-282
Closed Access | Times Cited: 1
Paul Triller, Bianca Raffaelli
Fortschritte der Neurologie · Psychiatrie (2024) Vol. 92, Iss. 07/08, pp. 277-282
Closed Access | Times Cited: 1
Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for the prevention of chronic migraine in a US tertiary headache center: A retrospective chart review study
Hsiangkuo Yuan, Fred Cohen, Maurice T. Driessen, et al.
Cephalalgia Reports (2024) Vol. 7
Open Access | Times Cited: 1
Hsiangkuo Yuan, Fred Cohen, Maurice T. Driessen, et al.
Cephalalgia Reports (2024) Vol. 7
Open Access | Times Cited: 1
Efficacy of eptinezumab in non-responders to subcutaneous monoclonal antibodies against CGRP and the CGRP receptor: A retrospective cohort study
Paul Triller, Virginia N. Blessing, Lucas Hendrik Overeem, et al.
Cephalalgia (2024) Vol. 44, Iss. 10
Closed Access | Times Cited: 1
Paul Triller, Virginia N. Blessing, Lucas Hendrik Overeem, et al.
Cephalalgia (2024) Vol. 44, Iss. 10
Closed Access | Times Cited: 1
(CGRP) Monocloncal antibodies
Claudia Altamura, Luigi Francesco Iannone, Luisa Fofi, et al.
Elsevier eBooks (2024), pp. 363-394
Closed Access
Claudia Altamura, Luigi Francesco Iannone, Luisa Fofi, et al.
Elsevier eBooks (2024), pp. 363-394
Closed Access
Switching from ligand to receptor anti‐calcitonin gene‐related peptide (CGRP ) antibodies or vice versa in non‐responders: A controlled cohort study
Nancy van Veelen, Britt W. H. van der Arend, E. Hiele, et al.
European Journal of Neurology (2024)
Open Access
Nancy van Veelen, Britt W. H. van der Arend, E. Hiele, et al.
European Journal of Neurology (2024)
Open Access
Effectiveness of switching strategies in CGRP monoclonal antibody therapy for migraine: A retrospective cohort study
Alex Jaimes, Andrea Gómez, Olga Pajares, et al.
Headache The Journal of Head and Face Pain (2024)
Closed Access
Alex Jaimes, Andrea Gómez, Olga Pajares, et al.
Headache The Journal of Head and Face Pain (2024)
Closed Access
Switching from calcitonin gene-related peptide monoclonal antibody monthly to fremanezumab quarterly based on the patient's preferred dosing schedule
Shiho Suzuki, Keisuke Suzuki, Tomohiko Shiina, et al.
Journal of the Neurological Sciences (2023) Vol. 455, pp. 122786-122786
Closed Access | Times Cited: 1
Shiho Suzuki, Keisuke Suzuki, Tomohiko Shiina, et al.
Journal of the Neurological Sciences (2023) Vol. 455, pp. 122786-122786
Closed Access | Times Cited: 1
